Anticorps Polyclonal de lapin anti-BRCA2

• Phare
• Validé par KD/KO

BRCA2 Polyclonal Antibody for ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

Publications(15)

N° de cat : 19791-1-AP

Synonymes

BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1

---

Galerie de données de validation

• 

  WB analysis of HeLa using 19791-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 19791-1-AP (BRCA2 antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

---

Applications publiées

• KD/KO: See 1 publications below
• WB: See 12 publications below
• IHC: See 3 publications below

Informations sur le produit

19791-1-AP cible BRCA2 dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: breast cancer 2, early onset
• Masse moléculaire calculée: 384 kDa
• Numéro d’acquisition GenBank: NM_000059
• Symbole du gène: BRCA2
• Identification du gène (NCBI): 675
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).

Publications

Species	Application	Title
human	WB	Nucleic Acids Res; LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA.; Authors - Liping Shen
human	WB	Int J Biol Macromol; Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation; Authors - Hong-Yu Tao
human	WB	Elife; LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells; Authors - Bo-Ruei Chen
human	WB	J Med Chem; Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA; Authors - Limei Ji
human	WB	Pharmacol Res; FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.; Authors - Shi-Qi Wu
human	WB	Mol Cancer; The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.; Authors - Yan Wang ; KD Validated

{{ptg:RelatedPrimaryAntibodies}}